A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorBeijing Institute of Heart, Lung and Blood Vessel Diseases

About this trial

Takayasu arteritis is a chronic vasculitis mainly involving the aorta and its main branches such as the brachiocephalic, carotid, subclavian, vertebral, and renal arteries, as well as the coronary and pulmonary arteries. Inflammation causes segments of the vessels to become narrowed, blocked, or even stretched, possibly resulting in aneurysms. The disease is very rare but most commonly occurs in young Asian women. However, there is a considerable lack of understanding of the disease mechanism of Takayasu arteritis. Initially, the disease remains clinically silent (or remains undetected) until the patients present with vascular occlusion. Additionally, many individuals with Takayasu arteritis, however, have no apparent symptoms despite disease activity. Therefore, biomarkers for diagnosis and monitor disease activity in individuals with Takayasu arteritis are needed. In this study, the investigators therefore to use different methods to identify new biomarkers for diagnosing or monitoring the disease activity in individuals with Takayasu arteritis. These biomarkers may provide valuable insights into the underlying biochemical processes and aid the understanding of the pathophysiology of this disease.

Eligibility criteria

Qualifiers

Age of onset ≤40 years,

Claudication of upper or lower extremities,

Decreased pulsation of 1 or both brachial arteries,

Difference of ≥ 10 mmHg in systolic blood pressure between arms,

Disqualifiers

Arteriographic lesions that could be entirely due to atherosclerosis,

Suffer from other autoimmune diseases (eg, ANCA-associated vasculitis, systemic lupus erythematosus, etc.) besides Takayasu arteritis,

Cogan's syndrome,

Behcet's disease,

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Lead sponsor

Shanghai Zhongshan Hospital

Collaborator

Peking University People's Hospital

Collaborator